DE3270055D1 - Chemical complex - Google Patents

Chemical complex

Info

Publication number
DE3270055D1
DE3270055D1 DE8282100450T DE3270055T DE3270055D1 DE 3270055 D1 DE3270055 D1 DE 3270055D1 DE 8282100450 T DE8282100450 T DE 8282100450T DE 3270055 T DE3270055 T DE 3270055T DE 3270055 D1 DE3270055 D1 DE 3270055D1
Authority
DE
Germany
Prior art keywords
chemical complex
complex
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8282100450T
Other languages
English (en)
Inventor
Harry Phillip Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of DE3270055D1 publication Critical patent/DE3270055D1/de
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
DE8282100450T 1981-01-23 1982-01-22 Chemical complex Expired DE3270055D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8102124 1981-01-23

Publications (1)

Publication Number Publication Date
DE3270055D1 true DE3270055D1 (en) 1986-04-30

Family

ID=10519177

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8282100450T Expired DE3270055D1 (en) 1981-01-23 1982-01-22 Chemical complex

Country Status (10)

Country Link
US (1) US4555504A (de)
EP (1) EP0056995B1 (de)
JP (1) JPS57182301A (de)
AU (1) AU558787B2 (de)
CA (1) CA1222742A (de)
DE (1) DE3270055D1 (de)
IE (1) IE52500B1 (de)
IT (1) IT1147806B (de)
NZ (1) NZ199543A (de)
ZA (1) ZA82447B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3372705D1 (en) * 1982-04-30 1987-09-03 Takeda Chemical Industries Ltd Pharmaceutical composition and its use
US4675395A (en) * 1984-03-14 1987-06-23 Seiwa Technological Laboratories Limited Cyclodextrin inclusion compound and process for its preparation
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4764601A (en) * 1985-10-18 1988-08-16 The Ohio State University Research Foundation Composition for assaying cardiac glycosides from serum or plasma
JPS6333341A (ja) * 1986-07-28 1988-02-13 Seitetsu Kagaku Co Ltd 配糖体の処理方法
US4798804A (en) * 1987-02-05 1989-01-17 Syntex (U.S.A.) Inc. Serum pretreatment in digoxin immunoassay
HU201685B (en) * 1987-04-23 1990-12-28 Chinoin Gyogyszer Es Vegyeszet For producing pharmaceutical compositions for inhalation and compositions for scenting air containing volatile active component in cyclodextrine inclusion, and air-scenting composition
US4840679A (en) * 1987-07-08 1989-06-20 American Maize-Products Company Purification and separation of branched beta-cyclodextrins
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
SI8810082A8 (en) * 1988-01-18 1995-12-31 Lek Tovarna Farmacevtskih Process for preparing new inclusion complex of nicardipine or its hydrochloride with beta-cyclodextrine
US5223295A (en) * 1988-01-22 1993-06-29 Asterol International Process for the elimination of steroid compounds contained in substance of biological origin
US5229370A (en) * 1988-08-15 1993-07-20 Ammeraal Robert N Water soluble branched beta cyclodextrin steroid complex
EP0381747A4 (en) * 1988-08-15 1991-09-11 American Maize-Products Company Water soluble branched beta cyclodextrin steroid complex
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5703088A (en) * 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5574041A (en) * 1990-03-16 1996-11-12 Beth Israel Hospital Association Use of spiperone derivatives as immunosuppressant agents
WO1991013622A1 (en) * 1990-03-16 1991-09-19 Beth Israel Hospital Association Use of spiperone as an immunosuppressant and anti-inflammatory agent
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5693645A (en) * 1992-12-23 1997-12-02 Beth Israel Deaconess Medical Center, Inc. Use of spiperone or spiperone derivatives as immunosuppressant agents
US5362860A (en) * 1993-02-01 1994-11-08 Warner-Lambert Company Neutral stabilization complex for CI-979 HCl, a cognition activator
US5658390A (en) * 1994-06-29 1997-08-19 American Maize-Products Company Purification of beta cyclodextrin
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US7074824B2 (en) * 2001-07-31 2006-07-11 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US6962944B2 (en) 2001-07-31 2005-11-08 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US20050026849A1 (en) * 2003-03-28 2005-02-03 Singh Chandra U. Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
US20060205679A1 (en) * 2004-10-22 2006-09-14 Azaya Therapeutics, Inc. Topical and oral formulations of cardiac glycosides for treating skin diseases
US20070009531A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010478A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
WO2010017480A1 (en) * 2008-08-07 2010-02-11 Centrose, Llc Glycoside compounds and pharmaceutical compositions thereof
IN2012DN03025A (de) 2009-09-09 2015-07-31 Ct Se Llc
JP2013530677A (ja) * 2010-02-08 2013-08-01 ザ コカ・コーラ カンパニー 溶解度を高めたテルペングリコシド
CA2837232A1 (en) * 2011-06-03 2012-12-06 Ratiopharm Gmbh Pharmaceutical composition comprising dapagliflozin and cyclodextrin
EP3411047B1 (de) 2016-02-04 2021-04-14 Czap Research And Development, LLC Trägerstoffe mit kontrollierter freisetzung und stratifiziertem cyclodextrineinschlusskomplex

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE513723A (de) * 1900-01-01
DE895769C (de) * 1951-08-26 1953-11-05 Knoll Ag Verfahren zur Herstellung von Einschlussverbindungen physiologisch wirksamer organischer Verbindungen
US3541077A (en) * 1968-05-31 1970-11-17 Cpc International Inc Method of preparing pure alpha-cyclodextrin
JPS50160416A (de) * 1974-06-24 1975-12-25
JPS51118817A (en) * 1975-04-08 1976-10-19 Nippon Shinyaku Co Ltd A process for preparing absorbable steroid glycoside pharmaceutical
JPS5762297A (en) * 1980-10-01 1982-04-15 Mitsubishi Yuka Yakuhin Kk Digitalis cardiac glycoside-cyclodextrin inclusion compound

Also Published As

Publication number Publication date
JPS57182301A (en) 1982-11-10
IE52500B1 (en) 1987-11-25
CA1222742A (en) 1987-06-09
AU7973482A (en) 1982-07-29
AU558787B2 (en) 1987-02-12
EP0056995A1 (de) 1982-08-04
ZA82447B (en) 1983-09-28
EP0056995B1 (de) 1986-03-26
NZ199543A (en) 1985-04-30
IT1147806B (it) 1986-11-26
US4555504A (en) 1985-11-26
IT8247635A0 (it) 1982-01-22
IE820136L (en) 1982-07-23

Similar Documents

Publication Publication Date Title
DE3270055D1 (en) Chemical complex
GB2114570B (en) Chemical compounds
GB2097692B (en) Combining chemical reagents
ZW9782A1 (en) Chemical compounds
ZA821642B (en) Processes
DE3269822D1 (en) Chemical sensor
PT74367B (en) Chemical process
GB2108955B (en) Chemical compounds
PT74366A (en) Chemical process
CS635982A2 (en) Ustroji k rozprostirani usni
GB2107703B (en) Chemical compounds
CS467082A1 (en) Predehrivaci buben k mandlu
ZA828185B (en) Chemical process
PT74538B (en) Chemical compound
CS713282A1 (en) Zpusob vyroby vsazkovych kriket k vyrobe karbidu vapenateho
CS52982A1 (en) Zarizeni k vyrobe licich forem
ZA825997B (en) Chemical compounds
ZA823278B (en) Chemical process
CS89682A1 (en) Zarizeni k regulaci vratneho pohybu rozteraciho valce
CS638282A1 (en) Zarizeni k tepelne ochrane topnych clanku
CS869681A1 (en) Schematicke zarizeni k riznemu zdroji proudu
IE820271L (en) Chemical compounds
CS355781A1 (en) Stroj k ohybani trubek
CS182981A1 (en) Zarizeni k oddelovani soucasti textilnich vyrobku
CS265781A1 (en) Zarizeni k elektrochemickemu cisteni znecistene kapaliny

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee